News & Events

Events 2007

ASIPI/INTA – São Paulo
INTA/ASIPI Conference 2007
March 10 to 14
São Paulo, Brazil
www.asipi.org
www.inta.org

LESANZ 2007 Annual Conference
March 15-17
www.lesanz.org.au

ABA/IPL 22nd Annual Intellectual Property Law Conference, Crystal Gateway Marriott Hotel, Arlington, VA;
April 12–14
www.abanet.org/intelprop

IACC – Chicago
2007 Spring Conference
April 25 to 27
Chicago, USA
www.iacc.org

AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION,
Spring Meeting, The Seaport Hotel & World Trade Center, Boston, MA (703-415-0780)
May 9–11
www.aipla.org

LES USA-Canada Spring Meeting
May 16-18
www.lesi.org

AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION,
Advanced Patent Prosecution Seminar, Washington, DC (703-415-0780)
June 7
www.aipla.org

AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION,
Advanced Patent Litigation Seminar, Washington, DC (703-415-0780)
June 8
www.aipla.org

LESI Annual Conference, Zurich
Jun 17-20
www.lesi.org

Forum & Executive Committee Meeting
October 4-10, 2007
Singapore

ASIPI - Cartagena
XIII Work Sessions and Administrative Council
November, 2007
Cartagena, Colombia
www.asipi.org

INTA – Lisboa – Portugal
What's Cooking in Europe?
December 3 – 4 2007
Lisboa, Portugal
www.inta.org

News

Biotechnology

Biotechnology has had great impact in the health field.

It is influenced in a decisive way on the industrial sectors related to medicine, specially pharmaceutical and chemical.

Some of them say that a global threat for the development of the sector is the system of Patents: in some countries there have been published clear rules about patentability of human genes, requiring from the patent a specific description, essential and useful credibility for the gene. In the other hand, some judicial cases that decided against the offenders who made changes in the invention patents, gives some judicial support to patents systems whenever it has a rational use.

Also, there are socioeconomics and legislatives barriers which affect in the development of the area.

The Medicine History has changed after the human genome secuenciation. The principal paradigm will consist in the concept of illness, which will be classified in the abnormal genetic expression that would be produced in the cell or affected cells.

In the cancer treatment there has been important progress in this sense.

They foresee that first illnesses which will be benefit of genomita are cancer, metabolic diseases, and others from Central Nervous System (especially Parkinson and Alzheimer)

In Paraguay we can see the implementation of therapies based on biotechnology’s products, so it revolutionizes diseases like cancer, hepatitis and others. The principal handicap for using this method in our country is the high cost of the treatment.